- Home
- LLAP vs STTK Comparison
LLAP vs STTK Comparison
Compare LLAP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLAP
- STTK
- Stock Information
- Founded
- LLAP 2013
- STTK 2016
- Country
- LLAP United States
- STTK United States
- Employees
- LLAP N/A
- STTK N/A
- Industry
- LLAP Military/Government/Technical
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- LLAP Industrials
- STTK Health Care
- Exchange
- LLAP Nasdaq
- STTK Nasdaq
- Market Cap
- LLAP 165.7M
- STTK 173.6M
- IPO Year
- LLAP N/A
- STTK 2020
- Fundamental
- Price
- LLAP $0.25
- STTK $3.86
- Analyst Decision
- LLAP Buy
- STTK Strong Buy
- Analyst Count
- LLAP 3
- STTK 3
- Target Price
- LLAP $2.58
- STTK $10.67
- AVG Volume (30 Days)
- LLAP 9.0M
- STTK 150.7K
- Earning Date
- LLAP 08-12-2024
- STTK 11-07-2024
- Dividend Yield
- LLAP N/A
- STTK N/A
- EPS Growth
- LLAP N/A
- STTK N/A
- EPS
- LLAP N/A
- STTK N/A
- Revenue
- LLAP $133,107,000.00
- STTK $4,123,999.00
- Revenue This Year
- LLAP $8.71
- STTK $164.45
- Revenue Next Year
- LLAP $34.59
- STTK N/A
- P/E Ratio
- LLAP N/A
- STTK N/A
- Revenue Growth
- LLAP 10.75
- STTK 380.09
- 52 Week Low
- LLAP $0.23
- STTK $1.33
- 52 Week High
- LLAP $1.62
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- LLAP 26.22
- STTK 57.18
- Support Level
- LLAP $0.24
- STTK $3.37
- Resistance Level
- LLAP $0.25
- STTK $3.75
- Average True Range (ATR)
- LLAP 0.01
- STTK 0.24
- MACD
- LLAP 0.02
- STTK 0.08
- Stochastic Oscillator
- LLAP 12.42
- STTK 88.57
About LLAP Terran Orbital Corporation
Terran Orbital Corp is a manufacturer of satellite products primarily serving the aerospace and defense industries. The company provide end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of our military, civil, and commercial customers. Geographically company operates in United States and Europe. Majority of the revenue is generated from United States.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.